Baird Defends Soleno Therapeutics Inc. (SLNO): 'Selloff on Likely Unrelated Patient Death Strengthens Buying Opportunity'
Tweet Send to a Friend
Baird analyst Brian Skorney reiterated an Outperform rating and $121.00 price target on Soleno Therapeutics Inc. (NASDAQ: SLNO).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
